NEWS & RESOURCES

PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer

PrognomiQ – a California-based healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced early results from the largest, deep multi-omics study, demonstrating the power of diverse molecular biomarkers to improve sensitivity and specificity in the early detection of cancer.

Read the full article here.